 SOUTH SAN FRANCISCO, Calif., July 29, 2021 PRNewswire -- Vaxart, Inc. Nasdaq: VXRT today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. 